Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer (NCT07140900)
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- University of California San Francisco — San Francisco, California
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Cleveland Clinic Foundation — Cleveland, Ohio
- Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center Hillman Cancer Center — Pittsburgh, Pennsylvania
- South Texas Accelerated Research Therapeutics - Carolinas — Myrtle Beach, South Carolina
- Sarah Cannon Research Institute — Nashville, Tennessee
- Chris OBrien Lifehouse — Camperdown, New South Wales
- Calvary Mater Newcastle Hospital — Waratah, New South Wales
- Cabrini Hospital — Clayton, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- The Alfred Hospital — Melbourne, Victoria
- Kantonsspital Graubuenden — Chur,
- Centre Hospitalier Universitaire Vaudois — Lausanne,
- Kantonsspital Sankt Gallen — Sankt Gallen,
📞 Contact the Study Coordinator
Phone: (866) 572-6436
Email: medinfo@amgen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) — Ottawa, Ontario
- RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Washington D.C., District of Columbia
- Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer — Salt Lake City, Utah
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Birmingham, Alabama
Explore by condition: All Metastatic Hormone-sensitive Prostate Cancer (mHSPC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.